Sobrevida de pacientes com doença falciforme diagnosticados durante a triagem neonatal: revisão sistemática

Autores

DOI:

https://doi.org/10.33448/rsd-v10i11.19329

Palavras-chave:

Doença falciforme; Triagem neonatal; Análise de sobrevida; Epidemiologia; Enfermagem baseada em evidências.

Resumo

Objetivo: Analisar os dados relativos à sobrevida de pacientes com doença falciforme diagnosticados durante o processo de triagem neonatal. Método: Revisão sistemática, realizada nas bases eletrônicas Current Index to Nursing and Allied Health Literature, Cochrane Library, National Library of Medicine, Scopus e Web of Science com descritores controlados indexados no Medical Subject Headings. Sem delimitação temporal ou de idioma. Resultados: Sete artigos compuseram a amostra final, todos publicados em inglês e de delineamento de coorte. A avaliação de risco de vieses pelo Newcastle Otawa Scale indicou que seis artigos foram considerados de alta qualidade. Foram estudadas as taxas de sobrevida global, estratificadas por genótipos, eventos clínicos agudos, sexo e níveis de hemoglobina, além da sobrevida livre de eventos. A sobrevida global apresentou variação entre 100% aos seis meses e 85,6% aos 18 anos, enquanto para o genótipo Sβº foi estimada em 55,2% aos 40 anos. Conclusão: Houve diminuição da sobrevida após os 30 anos de idade, entretanto, com aumento anual entre os períodos estudados. A elaboração de políticas públicas com inserção da comunidade no contexto de suas ações pode auxiliar na manutenção das estratégias de melhoria da sobrevida desta população.

Referências

Abboud, M. R. (2020). Standard management of sickle cell disease complications. Hematol Oncol Stem Cell Ther. https://pubmed.ncbi.nlm.nih.gov/32202245/

Araujo, O. M. R., Ivo, M. L., Ferreira Júnior, M. A., Pontes, E. R. J. C., Bispo, I. M. G. P., & Oliveira, E. C. L. d. (2015). Survival and mortality among users and non-users of hydroxyurea with sickle cell disease. Rev Lat Am Enfermagem, 23, 67-73. http://dx.doi.org/10.1590/0104-1169.3385.2526

Ballas, S. K. (2020). The evolving pharmacotherapeutic landscape for the treatment of Sickle Cell Disease. Mediterr J Hematol Infect Dis, 12(1). https://pubmed.ncbi.nlm.nih.gov/31934320/

Brasil. (2002). Manual de Normas Técnicas e Rotinas Operacionais do Programa Nacional de Triagem Neonatal (pp. 90). Retrieved from https://bvsms.saude.gov.br/bvs/publicacoes/triagem_neonatal.pdf

Brasil. (2005). Portaria nº 1.391 de 16 de Agosto de 2005: Institui no âmbito do Sistema Único de Saúde-SUS, as diretrizes para a Política Nacional de Atenção Integral às Pessoas com Doença Falciforme e outras Hemoglobinopatias.Brasília: Ministério da Saúde.

Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., Ashley‐Koch, A. E., & Telen, M. J. (2014). Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol, 89(5), 530-535. https://pubmed.ncbi.nlm.nih.gov/24478166/

Fernandes, A. P. P. C., Nélio Januário, J., Blanco Cangussu, C., Lino de Macedo, D., & Borato Viana, M. (2010). Mortality of children with sickle cell disease: A population study. J Pediatr (Rio J), 86(4). http://dx.doi.org/10.1590/S0021-75572010000400006

Gardner, K., Douiri, A., Drasar, E., Allman, M., Mwirigi, A., Awogbade, M., & Thein, S. L. (2016). Survival in adults with sickle cell disease in a high-income setting. Blood, 128(10), 1436-1438. https://pubmed.ncbi.nlm.nih.gov/27439910/

Hankins, J. S., Estepp, J. H., Hodges, J. R., Villavicencio, M. A., Robison, L. L., Weiss, M. J., Kang, G., Schreiber, J. E., Porter, J. S., & Kaste, S. C. (2018). Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood. Pediatr Blood Cancer, 65(9), e27228. https://pubmed.ncbi.nlm.nih.gov/29797644/

Houwing, M., de Pagter, P., van Beers, E., Biemond, B., Rettenbacher, E., Rijneveld, A., Schols, E., Philipsen, J., Tamminga, R., & van Draat, K. F. (2019). Sickle cell disease: Clinical presentation and management of a global health challenge. Blood Rev, 37, 100580. https://pubmed.ncbi.nlm.nih.gov/31128863/

Houwing, M. E., Buddenbaum, M., Verheul, T. C., de Pagter, A. P., Philipsen, J. N., Hazelzet, J. A., & Cnossen, M. H. (2021). Improving access to healthcare for paediatric sickle cell disease patients: a qualitative study on healthcare professionals’ views. BMC Health Serv Res, 21(1), 1-13. https://pubmed.ncbi.nlm.nih.gov/33712013/

Hulihan, M., Hassell, K. L., Raphael, J. L., Smith-Whitley, K., & Thorpe, P. (2017). CDC Grand Rounds: Improving the Lives of Persons with Sickle Cell Disease. MMWR. Morbidity and mortality weekly report, 66(46), 1269-1271. https://pubmed.ncbi.nlm.nih.gov/29166365/ doi:10.15585/mmwr.mm6646a2

Institute for Health Metrics and Evaluation. (2018). Both Sexes, All ages, 1990-2016, YLLs per 100.000. http://www.healthdata.org/

Kanter, J., Smith, W. R., Desai, P. C., Treadwell, M., Andemariam, B., Little, J., Nugent, D., Claster, S., Manwani, D. G., & Baker, J. (2020). Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv, 4(16), 3804-3813. https://pubmed.ncbi.nlm.nih.gov/32785684/

Kikuchi, B. A., Ivo, M. L., Barbieri, A. R., Camargo Filho, R., Amargo Filho, R., & Nascimento, V. (2018). Evaluation of the implantation of the national neonatal screening program regarding coverage index, disease prevalence and sickle cell trait in Mato Grosso do Sul-Brazil: 2001–2015. IJDR, 8(3), 19279-19283. https://www.journalijdr.com/evaluation-implantation-national-neonatal-screening-program-regarding-coverage-index-disease

King, L., Fraser, R., Forbes, M., Grindley, M., Ali, S., & Reid, M. (2007). Newborn sickle cell disease screening: the Jamaican experience (1995–2006). J Med Screen, 14(3), 117-122. https://pubmed.ncbi.nlm.nih.gov/17925083/

Kloda, L. A., & Bartlett, J. C. (2013). Formulating answerable questions: question negotiation in evidence-based practice. J Can Health Libr Assoc, 34(2), 55-60. https://journals.library.ualberta.ca/jchla/index.php/jchla/article/view/22636

Lê, P.-Q., Ferster, A., Dedeken, L., Vermylen, C., Vanderfaeillie, A., Rozen, L., Heijmans, C., Huybrechts, S., Devalck, C., & Cotton, F. (2018). Neonatal screening improves sickle cell disease clinical outcome in Belgium. J Med Screen, 25(2), 57-63. DOI: 10.1177/0969141317701166

Lee, A., Thomas, P., Cupidore, L., Serjeant, B., & Serjeant, G. (1995). Improved survival in homozygous sickle cell disease: lessons from a cohort study. Bmj, 311(7020), 1600-1602. https://pubmed.ncbi.nlm.nih.gov/8555802/

Lee, L., Smith-Whitley, K., Banks, S., & Puckrein, G. (2019). Reducing Health Care Disparities in Sickle Cell Disease: A Review. Public Health Reports, 134(6), 599-607. https://pubmed.ncbi.nlm.nih.gov/31600481/ doi:10.1177/0033354919881438

Lubeck, D., Agodoa, I., Bhakta, N., Danese, M., Pappu, K., Howard, R., Gleeson, M., Halperin, M., & Lanzkron, S. (2019). Estimated Life Expectancy and Income of Patients With Sickle Cell Disease Compared With Those Without Sickle Cell Disease. JAMA Netw Open, 2(11), e1915374-e1915374. https://pubmed.ncbi.nlm.nih.gov/31730182/

Mallmann, M. B., Tomasi, Y. T., & Boing, A. F. (2020). Realização dos testes de triagem neonatal no Brasil: prevalências e desigualdades regionais e socioeconômicas. J. Pediatr, 96(4), 487-494. http://dx.doi.org/10.1016/j.jped.2019.02.008

Mbiya, B. M., Kalombo, D. K., Mukendi, Y. N., Mpoyi, J. K., Biboyi, P. M., Daubie, V., Disashi, G. T., & Gulbis, B. (2020). Improvement of Sickle Cell Disease Morbimortality in Children: Experience in a Remote Area of an African Country. Research Square. doi: 10.20944 / preprints202005.0305.v2

Mburu, J., & Odame, I. (2019). Sickle cell disease: Reducing the global disease burden. Int J Lab Hematol, 41(S1), 82-88. https://doi.org/10.1111/ijlh.13023

McGann, P. T. (2016). Time to invest in sickle cell anemia as a global health priority. Pediatrics, 137(6). https://pubmed.ncbi.nlm.nih.gov/27244863/

Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., & Stewart, L. A. (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev, 4(1), 1. https://pubmed.ncbi.nlm.nih.gov/25554246/

Nnodu, O. E., Sopekan, A., Nnebe-Agumadu, U., Ohiaeri, C., Adeniran, A., Shedul, G., Isa, H. A., Owolabi, O., Chianumba, R. I., & Tanko, Y. (2020). Implementing newborn screening for sickle cell disease as part of immunisation programmes in Nigeria: a feasibility study. Lancet Haematol, 7(7), e534-e540. https://pubmed.ncbi.nlm.nih.gov/32589979/

Odame, I., & Jain, D. (2020). Sickle cell disease: Progress made & challenges ahead. Indian J Med Res, 151(6), 505. https://pubmed.ncbi.nlm.nih.gov/32719221/

Oron, A. P., Chao, D. L., Ezeanolue, E. E., Ezenwa, L. N., Piel, F. B., Ojogun, O. T., Uyoga, S., Williams, T. N., & Nnodu, O. E. (2020). Caring for Africa’s sickle cell children: will we rise to the challenge? BMC Med, 18, 1-8. https://pubmed.ncbi.nlm.nih.gov/32340612/

Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016). Rayyan—a web and mobile app for systematic reviews. Syst Rev, 5(1), 210. https://pubmed.ncbi.nlm.nih.gov/27919275/

Piel, F. B., Hay, S. I., Gupta, S., Weatherall, D. J., & Williams, T. N. (2013). Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions. PLoS Med, 10(7), e1001484. https://pubmed.ncbi.nlm.nih.gov/23874164/

Piel, F. B., Steinberg, M. H., & Rees, D. C. (2017). Sickle cell disease. N Engl J Med, 376(16), 1561-1573. https://www.nejm.org/doi/full/10.1056/NEJMra1510865?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

Quinn, C. T., Rogers, Z. R., & Buchanan, G. R. (2004). Survival of children with sickle cell disease. Blood, 103(11), 4023-4027. https://doi.org/10.1182/blood-2003-11-3758

Quinn, C. T., Rogers, Z. R., McCavit, T. L., & Buchanan, G. R. (2010). Improved survival of children and adolescents with sickle cell disease. Blood, 115(17), 3447-3452. https://doi.org/10.1182/blood-2009-07-233700

Ramos, J. T., de Amorim, F. S., Pedroso, F. K. F., Nunes, A. C. C., & Rios, M. A. (2015). Mortalidade por doença falciforme em estado do nordeste brasileiro. R. Enferm. Cent. O. Min. http://www.seer.ufsj.edu.br/index.php/recom/article/view/859

Runkel, B., Klüppelholz, B., Rummer, A., Sieben, W., Lampert, U., Bollig, C., Markes, M., Paschen, U., & Angelescu, K. (2020). Screening for sickle cell disease in newborns: a systematic review. Syst Rev, 9(1), 1-9. doi: 10.1186/s13643-020-01504-5

Sabarense, A. P., Lima, G. O., Silva, L. M., & Viana, M. B. (2015). Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program. J Pediatr (Rio J), 91(3), 242-247. https://pubmed.ncbi.nlm.nih.gov/25449790/

Sarat, C. N. F., Ferraz, M. B., Júnior, M. A. F., Souza, A. S. d., Cardoso, A. I. d. Q., & Ivo, M. L. (2019). Prevalence of sickle cell disease in adults with delayed diagnosis. Acta Paul Enferm, 32(2), 202-209. DOI: 10.1590/1982-0194201900028

Serjeant, G. R., Chin, N., Asnani, M. R., Serjeant, B. E., Mason, K. P., Hambleton, I. R., & Knight-Madden, J. M. (2018). Causes of death and early life determinants of survival in homozygous sickle cell disease: The Jamaican cohort study from birth. PloS one, 13(3), e0192710. https://pubmed.ncbi.nlm.nih.gov/29494636/

Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A., & Thacker, S. B. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Jama, 283(15), 2008-2012. https://pubmed.ncbi.nlm.nih.gov/10789670/

Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019). Pathophysiology of sickle cell disease. Annu Rev Pathol, 14, 263-292. 10.1146/annurev-pathmechdis-012418-012838

Telfer, P., Coen, P., Chakravorty, S., Wilkey, O., Evans, J., Newell, H., Smalling, B., Amos, R., Stephens, A., & Rogers, D. (2007). Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. haematologica, 92(7), 905-912. http://www.haematologica.org/content/92/7/905.long

Ware, R. E., de Montalembert, M., Tshilolo, L., & Abboud, M. R. (2017). Sickle cell disease. Lancet, 390(10091), 311-323. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30193-9/fulltext

Wells, G., Shea, B., O’Connell, D., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (2014). Newcastle-Ottawa quality assessment scale cohort studies. 15 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp

Wonkam, A., & Makani, J. (2019). Sickle cell disease in Africa: an urgent need for longitudinal cohort studies. Lancet Glob Health, 7(10), e1310-e1311. https://pubmed.ncbi.nlm.nih.gov/31451442/

Downloads

Publicado

24/08/2021

Como Citar

POMPEO, C. M.; FERREIRA JÚNIOR, M. A.; CARDOSO, A. I. de Q.; SOUZA, M. da C.; MOTA, F. M.; IVO, M. L. Sobrevida de pacientes com doença falciforme diagnosticados durante a triagem neonatal: revisão sistemática. Research, Society and Development, [S. l.], v. 10, n. 11, p. e95101119329, 2021. DOI: 10.33448/rsd-v10i11.19329. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/19329. Acesso em: 25 dez. 2024.

Edição

Seção

Ciências da Saúde